Hong Kong-listed biopharmaceutical stocks collectively strengthened, with BeiGene (06160.HK) rising more than 10%, Zai Lab (09688.HK) rising more than 9%, Tiger Pharmaceuticals (03347.HK) rising more than 8%, WuXi Biologics (02269.HK) rising more than 6%, WuXi AppTec (02359.HK) and Rongchang Biopharmaceuticals (09995.HK) rising more than 5%.

2025-02-21 15:33:49

BeiGene WuXi Biologics WuXi AppTec

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Singapore investigates Nvidia server export fraud
                            2025-03-03

                                    Shenzhen: By 2027, there will be more than 1,200 companies related to the embodied intelligent robot industry cluster
                            2025-03-03

                                    Hongqi Chain Store: Deputy General Managers Zhang Ying, Wan Chun, Hong Fan and Yang Yuanbin resigned
                            2025-03-03

                                    Shenzhen: Focus on supporting key core technologies such as core components of embodied intelligent robots, AI chips, and bionic dexterous hands
                            2025-03-03

                                    Intel showcases Xeon 6 processor-based network infrastructure at MWC2025
                            2025-03-03